Redirecting to http://www.jnj.com/news/all/US-FDA-Approves-YONDELIS-trabectedin-for-the-Treatment-of-Patients-with-Unresectable-or-Metastatic-Liposarcoma-or-Leiomyosarcoma...

Click here if your browser doesn't automatically take you to this page.